Abstract
Non-receptor SRC family kinases are critical for B-cell receptor signal transduction. Dasatinib, an SRC family kinase inhibitor used for the treatment of B-cell acute lymphoblastic leukemia (ALL), can interfere with this critical step of B-cell activation. We present the case of a patient on chronic dasatinib for B-cell. ALL who developed a common variable immunodeficiency (CVID)-like phenotype.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
